CG Oncology, Inc. Share-based Payment Arrangement, Expense
CG Oncology, Inc. (CGON) reported Share-based Payment Arrangement, Expense of $14.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06
- CG Oncology, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $14.33M, a 104.57% increase year-over-year.
- CG Oncology, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $6.47M, a 25.68% increase year-over-year.
- CG Oncology, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $7.19M, a 44.03% increase year-over-year.
- CG Oncology, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $7.33M, a 176.75% increase year-over-year.
- CG Oncology, Inc. share-based payment arrangement, expense for fiscal 2025 was $26.68M, a 133.96% increase from fiscal 2024.
- CG Oncology, Inc. share-based payment arrangement, expense for fiscal 2024 was $11.40M, a 646.20% increase from fiscal 2023.
- CG Oncology, Inc. share-based payment arrangement, expense for fiscal 2023 was $1.53M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.33M 10-Q · filed 2026-08-06 | $20.81M 10-Q · filed 2026-08-06 | $28.00M derived: sum of 3 quarters · filed 2026-08-06 | $35.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $6.47M 10-Q · filed 2026-05-08 | $13.66M derived: sum of 2 quarters · filed 2026-05-08 | $20.99M derived: sum of 3 quarters · filed 2026-05-08 | $28.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $7.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $14.52M derived: sum of 2 quarters · filed 2026-02-27 | $21.52M derived: sum of 3 quarters · filed 2026-08-06 | $26.68M 10-K · filed 2026-02-27 |
| 2025-09-30 | $7.33M 10-Q · filed 2025-11-14 | $14.34M derived: sum of 2 quarters · filed 2026-08-06 | $19.49M 10-Q · filed 2025-11-14 | $24.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $7.01M 10-Q · filed 2026-08-06 | $12.16M 10-Q · filed 2026-08-06 | $17.15M derived: sum of 3 quarters · filed 2026-08-06 | $19.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.15M 10-Q · filed 2026-05-08 | $10.14M derived: sum of 2 quarters · filed 2026-05-08 | $12.79M derived: sum of 3 quarters · filed 2026-05-08 | $15.04M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $4.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $7.64M derived: sum of 2 quarters · filed 2026-02-27 | $9.88M derived: sum of 3 quarters · filed 2026-02-27 | $11.40M 10-K · filed 2026-02-27 |
| 2024-09-30 | $2.65M 10-Q · filed 2025-11-14 | $4.89M derived: sum of 2 quarters · filed 2025-11-14 | $6.41M 10-Q · filed 2025-11-14 | $7.19M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $2.25M 10-Q · filed 2025-08-08 | $3.76M 10-Q · filed 2025-08-08 | $4.54M derived: sum of 3 quarters · filed 2026-02-27 | $4.93M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $1.52M 10-Q · filed 2025-05-13 | $2.29M derived: sum of 2 quarters · filed 2026-02-27 | $2.69M derived: sum of 3 quarters · filed 2026-02-27 | $2.87M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $778.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.17M derived: sum of 2 quarters · filed 2026-02-27 | $1.35M derived: sum of 3 quarters · filed 2026-02-27 | $1.53M 10-K · filed 2026-02-27 |
| 2023-09-30 | $394.00K 10-Q · filed 2024-11-12 | $571.00K derived: sum of 2 quarters · filed 2024-11-12 | $750.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $177.00K 10-Q · filed 2024-08-08 | $356.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $179.00K 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |